NO20045552L - Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes - Google Patents
Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendesInfo
- Publication number
- NO20045552L NO20045552L NO20045552A NO20045552A NO20045552L NO 20045552 L NO20045552 L NO 20045552L NO 20045552 A NO20045552 A NO 20045552A NO 20045552 A NO20045552 A NO 20045552A NO 20045552 L NO20045552 L NO 20045552L
- Authority
- NO
- Norway
- Prior art keywords
- disorder
- serotonin reuptake
- anxiety
- reuptake inhibitor
- disorders
- Prior art date
Links
- 239000003772 serotonin uptake inhibitor Substances 0.000 title abstract 3
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 abstract 1
- 208000026345 acute stress disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000019899 phobic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002469 receptor inverse agonist Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Radiation-Therapy Devices (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Finger-Pressure Massage (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39085102P | 2002-06-20 | 2002-06-20 | |
| DKPA200200943 | 2002-06-20 | ||
| PCT/DK2003/000412 WO2004000326A1 (en) | 2002-06-20 | 2003-06-19 | Combination therapy wherein a serotonin reuptake inhibitor is used |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045552L true NO20045552L (no) | 2004-12-20 |
Family
ID=30001771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045552A NO20045552L (no) | 2002-06-20 | 2004-12-20 | Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050288355A1 (de) |
| EP (1) | EP1545552B1 (de) |
| JP (1) | JP2005533069A (de) |
| KR (1) | KR20050012284A (de) |
| CN (1) | CN100430063C (de) |
| AT (1) | ATE357920T1 (de) |
| AU (1) | AU2003240434A1 (de) |
| BR (1) | BR0311503A (de) |
| CA (1) | CA2490638C (de) |
| DE (1) | DE60312874T2 (de) |
| DK (1) | DK1545552T3 (de) |
| ES (1) | ES2282632T3 (de) |
| IL (1) | IL165840A0 (de) |
| MX (1) | MXPA04012693A (de) |
| NO (1) | NO20045552L (de) |
| NZ (1) | NZ536624A (de) |
| PL (1) | PL373729A1 (de) |
| PT (1) | PT1545552E (de) |
| WO (1) | WO2004000326A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005018676A1 (en) * | 2003-08-21 | 2005-03-03 | H. Lundbeck A/S | The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression |
| AU2004283196B2 (en) * | 2003-09-17 | 2011-08-25 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds |
| EP2343073A3 (de) * | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Kombination eines Beruhigungsmittels und eines Neurotransmittermodulators und Verfahren zur Verbesserung der Schlafqualität und Behandlung von Depressionen |
| US7598255B2 (en) * | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| AU2008283989B2 (en) * | 2007-08-03 | 2013-12-05 | Richter Gedeon Nyrt. | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands. |
| CN107556206A (zh) * | 2016-06-30 | 2018-01-09 | 陕西合成药业股份有限公司 | 一种新型5‑羟色胺再摄取抑制剂类化合物及其制备方法和在医学上的应用 |
| US20200155687A1 (en) * | 2017-04-10 | 2020-05-21 | Shire Pharmaceuticals Inc. | Methods of treatment using an amphetamine prodrug |
| WO2020014302A1 (en) * | 2018-07-11 | 2020-01-16 | Rosenberg Leon I | Therapeutic combinations for treatment of cns disorders |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| PL4009942T3 (pl) * | 2019-08-06 | 2024-04-08 | Initiator Pharma A/S | Związek służący do leczenia skojarzonego |
| WO2025018810A1 (ko) * | 2023-07-18 | 2025-01-23 | 주식회사 지오비스타 | 동물에 대한 정신질환 또는 행동장애의 예방 또는 치료용 조성물 |
| CN117257815A (zh) * | 2023-11-20 | 2023-12-22 | 中国人民解放军军事科学院军事医学研究院 | Cgp35348在制备抗抑郁药物中的新用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9801538D0 (en) * | 1998-01-23 | 1998-03-25 | Merck Sharp & Dohme | Pharmaceutical product |
| US6176242B1 (en) * | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
-
2003
- 2003-06-19 EP EP03729907A patent/EP1545552B1/de not_active Expired - Lifetime
- 2003-06-19 PT PT03729907T patent/PT1545552E/pt unknown
- 2003-06-19 JP JP2004514582A patent/JP2005533069A/ja not_active Withdrawn
- 2003-06-19 MX MXPA04012693A patent/MXPA04012693A/es active IP Right Grant
- 2003-06-19 CN CNB038144387A patent/CN100430063C/zh not_active Expired - Fee Related
- 2003-06-19 KR KR10-2004-7020393A patent/KR20050012284A/ko not_active Ceased
- 2003-06-19 AT AT03729907T patent/ATE357920T1/de not_active IP Right Cessation
- 2003-06-19 DE DE60312874T patent/DE60312874T2/de not_active Expired - Fee Related
- 2003-06-19 DK DK03729907T patent/DK1545552T3/da active
- 2003-06-19 WO PCT/DK2003/000412 patent/WO2004000326A1/en not_active Ceased
- 2003-06-19 AU AU2003240434A patent/AU2003240434A1/en not_active Abandoned
- 2003-06-19 US US10/516,519 patent/US20050288355A1/en not_active Abandoned
- 2003-06-19 CA CA002490638A patent/CA2490638C/en not_active Expired - Fee Related
- 2003-06-19 BR BR0311503-8A patent/BR0311503A/pt not_active IP Right Cessation
- 2003-06-19 IL IL16584003A patent/IL165840A0/xx unknown
- 2003-06-19 NZ NZ536624A patent/NZ536624A/en unknown
- 2003-06-19 PL PL03373729A patent/PL373729A1/xx not_active Application Discontinuation
- 2003-06-19 ES ES03729907T patent/ES2282632T3/es not_active Expired - Lifetime
-
2004
- 2004-12-20 NO NO20045552A patent/NO20045552L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003240434A1 (en) | 2004-01-06 |
| JP2005533069A (ja) | 2005-11-04 |
| PT1545552E (pt) | 2007-06-15 |
| DE60312874T2 (de) | 2008-01-17 |
| NZ536624A (en) | 2008-04-30 |
| US20050288355A1 (en) | 2005-12-29 |
| DK1545552T3 (da) | 2007-08-06 |
| IL165840A0 (en) | 2006-01-15 |
| CN1662246A (zh) | 2005-08-31 |
| CN100430063C (zh) | 2008-11-05 |
| BR0311503A (pt) | 2005-02-22 |
| WO2004000326A1 (en) | 2003-12-31 |
| EP1545552B1 (de) | 2007-03-28 |
| MXPA04012693A (es) | 2005-03-23 |
| EP1545552A1 (de) | 2005-06-29 |
| DE60312874D1 (de) | 2007-05-10 |
| CA2490638A1 (en) | 2003-12-31 |
| ES2282632T3 (es) | 2007-10-16 |
| PL373729A1 (en) | 2005-09-05 |
| ATE357920T1 (de) | 2007-04-15 |
| CA2490638C (en) | 2008-01-22 |
| KR20050012284A (ko) | 2005-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20045552L (no) | Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes | |
| BRPI0514288A (pt) | benzamidas substituìdas com triflúor-metila como inibidores de cinases | |
| NO20053088L (no) | Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon. | |
| DE602005018758D1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| NO20072804L (no) | Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer | |
| NO20083204L (no) | Kombinasjon av en H3-antagonist/inversagonist og en appetittdemper | |
| NO20070081L (no) | Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer | |
| CY1114660T1 (el) | ΠΑΡΑΓΩΓΑ 2-ΑΔΑΜΑΝΤΥΛΟΥΡΙΑΣ ΩΣ ΕΚΛΕΚΤΙΚΟΙ ΑΝΑΣΤΟΛΕΙΣ 11β-HSD1 | |
| WO2008040360A3 (en) | Use of hypothermia inducing drugs to treat ischemia | |
| BR0208283A (pt) | Uso de escitaloprama, e, composição farmacêutica | |
| CL2011000061A1 (es) | Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia. | |
| NO20075920L (no) | Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria | |
| BR0306147A (pt) | Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição | |
| NO20063267L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og en histamin 3-reseptorantagonist, invers agonist eller partiell agonist | |
| JP2007513052A5 (de) | ||
| JP2006514952A5 (de) | ||
| EA200601158A1 (ru) | Комбинация ингибитора обратного захвата серотонина и антагониста, обратного агониста или частичного агониста рецептора гистамина 3 | |
| NO20061167L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon | |
| NO20035673L (no) | Nye heteroarylderivater, deres fremstilling og anvendelse | |
| NO20082201L (no) | Stabile farmasoytiske formuleringer inneholdende escitalopram og bupropion | |
| DE602005011988D1 (de) | Histamin-h3-rezeptor inhibitoren, ihre herstellung und therapeutische anwendungen | |
| CO5680440A2 (es) | Terapia de combinacion en donde se utiliza un inhibidor de recaptacion de serotonina | |
| NO20060229L (no) | Gaboxadol for behandling av depresjon og andre affektive lidelser | |
| EA200600453A1 (ru) | Комбинация ингибитора обратного захвата серотонина и ингибитора переносчика глицина типа 1 для лечения депрессии | |
| NO20062369L (no) | Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |